Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.5K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.

bioRxiv : the preprint server for biology·2026
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.

Science advances·2026
Same author

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.

The lancet. HIV·2026
Same author

Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Displayed and encoded antigens on adenovirus vectors optimize humoral and cellular immune responses in rhesus macaques.

Journal of virology·2026

Related Experiment Video

Updated: Mar 26, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.8K

Broadly Neutralizing Antibodies for HIV Eradication.

Kathryn E Stephenson1,2, Dan H Barouch3,4

  • 1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA.

Current HIV/AIDS Reports
|February 5, 2016
PubMed
Summary

Broadly neutralizing antibodies (bNAbs) offer a promising new strategy for HIV treatment and eradication. These potent antibodies neutralize a wide range of HIV-1 strains, targeting critical viral epitopes for enhanced therapeutic potential.

Keywords:
AntibodyBroadly neutralizing antibodiesEradicationHIVHIV pathogenesisHIV/AIDSReservoirReviewbNAb

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.8K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.0K

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • Passive antibody transfer has been explored for infectious diseases, including HIV, but early attempts were limited by narrow neutralization breadth and low potency.
  • Recent advancements have identified potent human monoclonal antibodies with broad neutralizing activity against diverse HIV-1 subtypes.

Purpose of the Study:

  • To review the application of broadly neutralizing antibodies (bNAbs) in HIV treatment and eradication strategies.
  • To highlight bNAbs targeting key HIV envelope epitopes, such as the CD4 binding site and V2/V3-glycan-dependent sites.

Main Methods:

  • Review of current scientific literature on broadly neutralizing antibodies (bNAbs) for HIV.
  • Discussion of antibody mechanisms targeting multiple HIV envelope epitopes.
  • Analysis of bNAbs in clinical development pipelines.

Main Results:

  • Discovery of potent bNAbs with broad neutralization capacity against multiple HIV-1 subtypes.
  • Identification of key epitopes targeted by effective bNAbs, including CD4 binding site and V2/V3-glycan-dependent sites.
  • Several bNAbs are progressing through clinical development for HIV therapy.

Conclusions:

  • Broadly neutralizing antibodies (bNAbs) represent a significant advancement in HIV therapeutic strategies.
  • The development of antibody combinations targeting multiple epitopes enhances neutralization potency and breadth.
  • bNAbs show considerable promise for both HIV treatment and potential eradication.